Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction
CA 2420852 A1 · Owner: Pfizer Limited · Inventors: Maw, Graham Nigel; Wayman, Christopher Peter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method of treating an individual is described. The method comprise delivering to the individual an agent that is capable of modulating an intermediate conductance calcium-activated potassium (IKCa) channel in the sexual genitalia of the individual; wherein the modulation of the IKCa channel by the agent is capable of mediating a relaxation of corpus cavernosal smooth muscle tone. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or exicipient.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 24, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 24, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 24, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.